期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 64, 期 13, 页码 1508-1521出版社
ELSEVIER
DOI: 10.1016/j.addr.2012.08.014
关键词
Short interfering RNA (siRNA); In vivo; Systemic delivery; Nanoparticles; Clinical trials; Personalized medicine
资金
- Marie Curie IRG-FP7 of the European Union
- Lewis Family Trust
- Israel Science Foundation [181/10, 41/11]
- Kenneth Rainin Foundation
- I-CORE Program of the Planning and Budgeting Committee
- FTA: Nanomedicines for Personalized Theranostics of the Israeli National Nanotechnology Initiative
RNA interference (RNAi) has just made it through the pipeline to clinical trials. However, in order for RNAi to serve as an ideal personalized therapeutics and be clinically approved safe, specific, and potent strategies must be devised for efficient delivery of RNAi payloads to specific cell types, which despite the immense potential, remains a challenge. Through evaluating the recent reported studies in this field, we introduce the progress in designing targeted nano-scaled strategies that are anticipated to overcome the delivery drawbacks and along with the exciting omics discipline to personalize RNAi-based therapeutics. (C) 2012 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据